Gelonghui, March 26, 丨 Aoxing Life Technology (06118.HK) announced that for the year ended December 31, 2023, the Group's total revenue was approximately RMB 1,763.7 million, a decrease of about 18.2% compared to the year ended December 31, 2022. This was mainly due to reduced revenue from the Fluid and Bioprocess Systems, Clean Room and Automated Control and Monitoring Systems, and Life Science Consumables business segments, partially offset by increased revenue from the Powder Solids Systems, Pharmaceutical Equipment Distribution and Agency business segments. The Group recorded an annual loss of RMB 151.3 million in the current year, while the annual profit for the year ended 31 December 2022 was approximately RMB 67.7 million.
As of December 31, 2023, the Group held 418 patents. During this year, the Group obtained 57 registered patents, and currently 62 patents are in the process of being applied for.